Document is current
Any future updates will be listed below
-
Authors
Niioka, Hirohiko
Kume, Teruyoshi
Kubo, Takashi
Soeda, Tsunenari
Watanabe, Makoto
Yamada, Ryotaro
Sakata, Yasushi
Miyamoto, Yoshihiro
Wang, Bowen
Nagahara, Hajime
Miyake, Jun
Akasaka, Takashi
Saito, Yoshihiko
Uemura, Shiro https://orcid.org/0000-0002-6089-5358
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (19ek0210121h0001)
- License Information
-
More Information
Article History
Received: 4 April 2022
Accepted: 12 August 2022
First Online: 18 August 2022
Competing interests
: T. Kume declares speaker honoraria from Abbott Vascular Japan. Y. S. declares speaker honoraria from Daiichi Sankyo, Otsuka Pharma, Mitsubishi Tanabe Pharma, Astellas Pharma, Kyowa Hakko Kirin, Kowa, AstraZeneca, Boehringer Ingelheim Japan, Takeda Yakuhin, Teijin Pharma, Bayer Yakuhin, Bristol-Myers Squibb, Novartis Pharma, MSD, Pfizer, Amgen, Siemens, Taisho Toyama Pharma, Nihon Shinyaku, Mochida Pharma, and Tsumura and research funds from Novartis Pharma, Roche Diagnostics, Bayer Yakuhin, Kowa, Ono Yakuhin, Mitsubishi Tanabe Pharma, Daiichi Sankyo, Otsuka Pharma, Astellas Pharma, Actelion Pharma, Kyowa Hakko Kirin, Shionogi Pharma, Dainippon Sumitomo Pharma, Takeda Yakuhin, Teijin Pharma, Bayer Yaku Inin, Bristol-Myers Squibb, Novartis Pharma, Asahi Kasei Pharma, MSD, Sanofi, Zeria Shinyaku, Chugai. S. U. declares speaker honoraria from Bayer Yakuhin and Daiichi Sankyo and research funds from Daiichi Sankyo, Medtronic, and Abbott Vascular. All of the other authors have nothing to disclose.
